<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Holford, N.H.</title>
    <link>http://repub.eur.nl/res/aut/13226/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children (Article)</title>
      <link>http://repub.eur.nl/res/pub/10292/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Descriptions of the pharmacokinetics and metabolism of
      morphine and its metabolites in young children are scant. Previous studies
      have not differentiated the effects of size from those related to age
      during infancy. METHODS: Postoperative children 0-3 yr old were given an
      intravenous loading dose of morphine hydrochloride (100 micro g kg(-1) in
      2 min) followed by either an intravenous morphine infusion of 10 micro g
      h(-1) kg(-1) (n=92) or 3-hourly intravenous morphine boluses of 30 micro g
      kg(-1) (n=92). Additional morphine (5 micro g kg(-1)) every 10 min was
      given if the visual analogue (VAS, 0-10) pain score was &gt;/=4. Arterial
      blood (1.4 ml) was sampled within 5 min of the loading dose and at 6, 12
      and 24 h for morphine, morphine-3-glucuronide (M3G) and
      morphine-6-glucuronide (M6G). The disposition of morphine and formation
      clearances of morphine base to its glucuronide metabolites and their
      elimination clearances were estimated using non-linear mixed effects
      models. RESULTS: The analysis used 1856 concentration observations from
      184 subjects. Population parameter estimates and their variability (%) for
      a one-compartment, first-order elimination model were as follows: volume
      of distribution 136 (59.3) litres, formation clearance to M3G 64.3 (58.8)
      litres h(-1), formation clearance to M6G 3.63 (82.2) litres h(-1),
      morphine clearance by other routes 3.12 litres h(-1) per 70 kg,
      elimination clearance of M3G 17.4 (43.0) litres h(-1), elimination
      clearance of M6G 5.8 (73.8) litres h(-1). All parameters are standardized
      to a 70 kg person using allometric 3/4 power models and reflect fully
      mature adult values. The volume of distribution increased exponentially
      with a maturation half-life of 26 days from 83 litres per 70 kg at birth;
      formation clearance to M3G and M6G increased with a maturation half-life
      of 88.3 days from 10.8 and 0.61 litres h(-1) per 70 kg respectively at
      birth. Metabolite formation decreased with increased serum bilirubin
      concentration. Metabolite clearance increased with age (maturation
      half-life 129 days), and appeared to be similar to that described for
      glomerular filtration rate maturation in infants. CONCLUSION: M3G is the
      predominant metabolite of morphine in young children and total body
      morphine clearance is 80% that of adult values by 6 months. A mean
      steady-state serum concentration of 10 ng ml(-1) can be achieved in
      children after non-cardiac surgery in an intensive care unit with a
      morphine hydrochloride infusion of 5 micro g h(-1) kg(-1) at birth (term
      neonates), 8.5 micro g h(-1) kg(-1) at 1 month, 13.5 micro g h(-1) kg(-1)
      at 3 months and 18 micro g h(-1) kg(-1) at 1 year and 16 micro g h(-1)
      kg(-1) for 1- to 3-yr-old children.</description>
    </item>
  </channel>
</rss>